Aclaris Therapeutics ACRS
$3.44 −$0.06 (-1.71%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $3.44 0.00%
Open$3.44
Prev close$3.50
Day range$3.40 – $3.55
Volume2.19M
Market cap$545.63M
P/E (TTM)–
Dividend yield–
Fundamentals
Latest reported quarter: Q3, ended Sep 2026
Revenue$1.48M-55.1% YoY
Operating profit-$21.94M-28.7% YoY
Net profit-$18.51M-26.7% YoY
Diluted EPS-$0.12+0.0% YoY
Free cash flow-$24.09M-119.9% YoY
Operating cash flow-$24.08M
Revenue, last 8 quarters
Net profit, last 8 quarters
Diluted EPS by quarter
Free cash flow by quarter
Annual revenue
Profitability & balance sheet
Gross margin5.8%
Operating margin-1,412.4%
Net margin-1,244.1%
Return on equity-55.5%
Return on assets-40.7%
Return on invested capital-60.2%
Current ratio5.09
Liabilities / assets22.8%
Cash & investments$114.29M
Net cash (debt)$114.29M
Income statement
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Revenue as Reported | $1.48M | $1.63M | $2.00M | $7.83M | $1.30M |
| Total Operating Revenue | $1.48M | $1.63M | $2.00M | $7.83M | $1.30M |
| Cost of Revenue | $1.32M | $1.45M | $1.79M | $7.28M | $1.47M |
| Gross Profit | $160,000.00 | $176,000.00 | $208,000.00 | $542,000.00 | -$174,000.00 |
| Operating Expense | $22.10M | $24.11M | $22.40M | $74.62M | $22.16M |
| Selling and Admin Expenses | $6.04M | $6.05M | $6.74M | $21.97M | $5.58M |
| -General & Admin Expense | $6.04M | $6.05M | $6.74M | $21.97M | $5.58M |
| Research & Development | $16.07M | $18.07M | $15.66M | $52.65M | $16.58M |
| Operating Profit | -$21.94M | -$23.94M | -$22.19M | -$74.08M | -$22.33M |
| Net Non-Operating Interest Income (Expense) | $1.85M | $1.76M | $1.51M | $7.64M | $1.63M |
| Non-Operating Interest Income | $1.85M | $1.76M | $1.51M | $7.64M | $1.63M |
| Other Income (Expense) | $1.59M | $672,000.00 | $854,000.00 | $1.52M | $905,000.00 |
| Special Income (Charges) | $600,000.00 | -$300,000.00 | $0.00 | -$2.30M | -$400,000.00 |
| -Less:Restructuring and Mergern & Acquisition | -$600,000.00 | $300,000.00 | $0.00 | $2.30M | $400,000.00 |
| Other Non-Operating Income (Expenses) | $985,000.00 | $972,000.00 | $854,000.00 | $3.82M | $1.31M |
| Pretax Profit | -$18.51M | -$21.51M | -$19.82M | -$64.92M | -$19.80M |
| Net Profit | -$18.51M | -$21.51M | -$19.82M | -$64.92M | -$19.80M |
| Profit from Continuing Operations | -$18.51M | -$21.51M | -$19.82M | -$64.92M | -$19.80M |
| Net Income to Parent Company | -$18.51M | -$21.51M | -$19.82M | -$64.92M | -$19.80M |
| Net Income to Common Stockholders | -$18.51M | -$21.51M | -$19.82M | -$64.92M | -$19.80M |
| Basic EPS | -$0.12 | -$0.15 | -$0.15 | -$0.53 | -$0.16 |
| Diluted EPS | -$0.12 | -$0.15 | -$0.15 | -$0.53 | -$0.16 |
Balance sheet
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Assets | $216.16M | $179.69M | $198.72M | $160.46M | $160.46M |
| Total Current Assets | $123.23M | $97.77M | $110.23M | $96.32M | $96.32M |
| Cash and Cash Equivalents & Short-Term Investments | $114.29M | $91.56M | $105.42M | $90.75M | $90.75M |
| -Cash and Cash Equivalents | $20.39M | $19.17M | $28.66M | $19.96M | $19.96M |
| -Short Term Investments | $93.90M | $72.39M | $76.76M | $70.79M | $70.79M |
| Receivables | $8.94M | – | – | – | – |
| -Accounts Receivable | $8.94M | – | – | – | – |
| Total Non-Current Assets | $92.93M | $81.93M | $88.49M | $64.14M | $64.14M |
| Net PPE | $624,000.00 | $664,000.00 | $750,000.00 | $761,000.00 | $761,000.00 |
| Investments and Advances | $90.31M | $79.07M | $85.37M | $60.61M | $60.61M |
| -Available for Sale Securities | $90.31M | $79.07M | $85.37M | $60.61M | $60.61M |
| Other Non-Current Assets | $1.99M | $2.20M | $2.37M | $2.77M | $2.77M |
| Total Liabilities | $49.36M | $55.11M | $55.07M | $57.38M | $57.38M |
| Total Current Liabilities | $24.22M | $28.24M | $27.37M | $28.65M | $28.65M |
| Payables | $9.07M | $15.52M | $14.73M | $13.16M | $13.16M |
| -Accounts Payable | $9.07M | $15.52M | $14.73M | $13.16M | $13.16M |
| Current Accrued Expenses | $4.32M | $3.08M | $3.85M | $3.49M | $3.49M |
| Current Deferred Liabilities | $3.97M | $3.98M | $3.97M | $3.94M | $3.94M |
| Other Current Liabilities | $2.81M | $2.79M | $2.77M | $2.75M | $2.75M |
| Total Non-Current Liabilities | $25.14M | $26.87M | $27.70M | $28.73M | $28.73M |
| Non-Current Deferred Liabilities | $13.33M | $14.31M | $15.29M | $16.17M | $16.17M |
| Other Non-Current Liabilities | $11.80M | $12.56M | $12.42M | $12.57M | $12.57M |
| Total Equity | $166.80M | $124.58M | $143.65M | $103.08M | $103.08M |
| Stockholders' Equity | $166.80M | $124.58M | $143.65M | $103.08M | $103.08M |
| Capital Stock | $1,000.00 | $1,000.00 | $1,000.00 | $1,000.00 | $1,000.00 |
| -Common Stock | $1,000.00 | $1,000.00 | $1,000.00 | $1,000.00 | $1,000.00 |
| -Preferred Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Additional Paid-In Capital | $1.20B | $1.13B | $1.13B | $1.07B | $1.07B |
| Retained Earnings | -$1.03B | -$1.01B | -$987.61M | -$967.78M | -$967.78M |
| Gains/Losses Not Affecting Retained Earnings | -$1.12M | -$304,000.00 | $22,000.00 | $610,000.00 | $610,000.00 |
| Other Current Assets | – | $6.21M | $4.81M | $5.57M | $5.57M |
Cash flow
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$24.08M | -$19.85M | -$18.15M | -$47.11M | -$13.13M |
| Net cash flow from continuing operations | -$24.08M | -$19.85M | -$18.15M | -$47.11M | -$13.13M |
| Net Income from Continuing Operations | -$18.51M | -$21.51M | -$19.82M | -$64.92M | -$19.80M |
| Depreciation & Depletion & Amortization | $100,000.00 | $107,000.00 | $102,000.00 | $454,000.00 | $102,000.00 |
| Other Non-Cash Items | -$600,000.00 | – | – | $2.30M | $400,000.00 |
| Change in Working Capital | -$8.09M | -$1.42M | -$1.63M | $2.67M | $3.24M |
| -Change in Prepaid Assets | -$2.91M | – | – | $6.14M | -$672,000.00 |
| -Change in Payables and Accrued Expense | -$4.20M | $770,000.00 | -$1.51M | $350,000.00 | $5.21M |
| -Change In Other Working Capital | -$985,000.00 | -$972,000.00 | -$854,000.00 | -$3.82M | -$1.31M |
| Net cash flow from investing | -$33.22M | $10.26M | -$30.93M | $48.37M | $10.37M |
| Net Cash Flow from Continuing Investing Activities | -$33.22M | $10.26M | -$30.93M | $48.37M | $10.37M |
| Net PPE Purchase and Sale | -$13,000.00 | -$58,000.00 | -$13,000.00 | -$111,000.00 | -$24,000.00 |
| Net Business Purchase and Sale | $0.00 | – | – | -$833,000.00 | $0.00 |
| Net Investment Purchase and Sale | -$33.21M | $10.32M | -$30.92M | $49.31M | $10.39M |
| Financing Cash Flow | $58.53M | $91,000.00 | $57.78M | -$5.86M | -$2.53M |
| Net Cash Flow from Continuing Financing Activities | $58.53M | $91,000.00 | $57.78M | -$5.86M | -$2.53M |
| Net Common Stock Issuance | $58.37M | $0.00 | $57.88M | $0.00 | $0.00 |
| Proceeds from Stock Option Exercised | $223,000.00 | $114,000.00 | $151,000.00 | $0.00 | $0.00 |
| Net Other Financing Charges | -$63,000.00 | -$23,000.00 | -$250,000.00 | -$5.86M | -$2.53M |
| Ending Cash Balance | $20.39M | $19.17M | $28.66M | $19.96M | $19.96M |
| Net Change in Cash | $1.23M | -$9.49M | $8.70M | -$4.61M | -$5.30M |
| Beginning Cash Balance | $19.17M | $28.66M | $19.96M | $24.57M | $25.26M |
| Free Cash Flow | -$24.09M | -$19.91M | -$18.16M | -$47.22M | -$13.16M |
| -Change in Receivables | – | – | $742,000.00 | – | – |
| Net Intangibles Purchase and Sale | – | – | $0.00 | $0.00 | – |
No comments yet — be the first to weigh in on ACRS.
Sign in to join the discussion.